Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes

被引:2
|
作者
Sereda, Elena E. [1 ,2 ]
Kolegova, Elena. S. [3 ]
Kakurina, Gelena V. [1 ,2 ]
Korshunov, Dmitriy A. [1 ]
Sidenko, Evgenia A. [1 ]
Doroshenko, Artem V. [4 ]
Slonimskaya, Elena M. [4 ]
Kondakova, Irina V. [1 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Tumor Biochem, Tomsk 634009, Russia
[2] Siberian State Med Univ, Fac Med & Biol, Dept Biochem & Mol Biol, Tomsk 634050, Russia
[3] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Canc Progress Biol, Tomsk, Russia
[4] Russian Acad Sci, Canc Res Inst, Dept Gen Oncol, Tomsk Natl Res Med Ctr, Tomsk, Russia
来源
关键词
Luminal breast cancer; hematogenous metastases; proteasomes activity; long-term outcome; prognosis; ESTROGEN-RECEPTOR-ALPHA; KAPPA-B; TARGET; PHOSPHORYLATION; UBIQUITYLATION; DEGRADATION; PROTEIN;
D O I
10.21037/tbcr-22-22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of the study was to analyze the relationship between the caspase-like (CL) and chymotrypsin-like (ChTL) activities of proteasomes and the 5-year overall and metastasis-free survival rates in patients with luminal breast cancer. Methods: The study included 117 patients with primary operable invasive breast cancer (T1-2N0-1M0). Tissue samples from breast cancer patients were obtained as a result of the radical mastectomy or breast conserving surgery, which was a first line of therapy. The ChTL and CL proteasomes activities in the tumor tissue and in the surrounding adjacent breast tissues were assessed using the fluorometric method. The coefficients of ChTL (cChTL) and CL (cCL) proteasomes activities were also determined. The coefficients were calculated as the ratio of the corresponding proteasomes activity in the tumor tissue to the surrounding adjacent breast tissues. Within 5 years of follow-up, hematogenous metastases occurred in 14% of patients with luminal A breast cancer, in 31% of patients with luminal B human epidermal growth factor receptor-2 (HER-2) negative and in 23% of patients with luminal B HER-2 positive breast cancers. The study protocol was approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center. Written informed consent was obtained from all patients. Results: An increase in the ChTL and CL proteasomes activities was shown in all studied molecular subtypes of breast cancer compared to adjacent tissues. It was found that the cChTL of >35.9 U/mg protein and the cCL of >2.21 in breast cancer patients were associated with the development of distant metastases. In patients with luminal A breast cancer, the 5-year metastasis-free survival rates were associated only with the value of cCL of proteasomes (log-rank test: P=0.008). In patients with luminal B HER-2 negative breast cancer, the 5-year metastasis-free survival rates were associated with the levels of ChTL and cCL proteasomes activities (log-rank test: P=0.02 and P=0.04, respectively). Conclusions: The data obtained on the correlation of 5-year metastasis-free survival rates with the level of proteasomes activities indicate the possibility of their use as additional prognostic criteria for breast cancer.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Hospital volume differences and five-year survival from breast cancer
    Roohan, PJ
    Bickell, NA
    Baptiste, MS
    Therriault, GD
    Ferrara, EP
    Siu, AL
    AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (03) : 454 - 457
  • [2] FIVE-YEAR OVERALL SURVIVAL IN PATIENTS WITH CERVICAL CANCER IN KAZAKHSTAN
    Kaidarova, D.
    Chingissova, Z.
    Adilbay, D.
    Dushimova, Z.
    Kukubassov, Y.
    Bolatbekova, R.
    Kurmanova, A.
    Satanova, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 302 - 302
  • [3] An Overview of Five-Year Survival in Rectal Cancer in Relation to Lymph Node Status
    Benedek, Zalan
    Boer, Szabolcs Todor
    Bauer, Orsolya
    Sardi, Kalman
    Todor, Attila
    Suciu, Nicolae
    Coro, Marius Florin
    CHIRURGIA, 2020, 115 (06) : 747 - 755
  • [4] Five-Year US Cancer Survival Is 65%
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (16): : 1610 - 1610
  • [5] Five-Year Survival
    Lyons, Paul
    FAMILY MEDICINE, 2012, 44 (04) : 275 - 276
  • [6] Five-year Relative Survival Rate of Breast Cancer in the USA, Europe and Japan
    Katanoda, Kota
    Matsuda, Tomohiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (06) : 611 - 611
  • [7] Five-year survival from breast cancer in Western Australia over a decade
    Clayforth, C.
    Fritschi, L.
    McEvoy, Sa
    Byrne, M. J.
    Ingram, D.
    Sterrett, G.
    Harvey, J. M.
    Joseph, D.
    Jamrozik, K.
    BREAST, 2007, 16 (04): : 375 - 381
  • [8] Predicting five-year survival in patients with small salivary glands cancer
    Koul, R.
    Butler, J.
    Abdoh, A.
    Dubey, A.
    Nason, R.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S37 - S38
  • [9] Five-year survival following resection for oesophageal cancer in 733 patients
    Launois, B
    Catheline, JM
    Landen, S
    Bardaxoglou, E
    Chareton, B
    Campion, JP
    GASTROENTEROLOGY, 1996, 110 (04) : A548 - A548
  • [10] Recurrence and Five-Year Survival in Colorectal Cancer Patients After Surgery
    Fatemi, Seyed Reza
    Pourhoseingholi, Mohamad Amin
    Asadi, Farshad
    Vahedi, Mohsen
    Pasha, Sara
    Alizadeh, Leila
    Zali, Mohammad Reza
    IRANIAN JOURNAL OF CANCER PREVENTION, 2015, 8 (04)